A series of 6-alkylaminopurine arabinosides were synthesized and found to inhibit variceila-zoster virus (VZV). The antiviral activities of these nucleosides were limited to VZV. None of the other viruses tested in the herpesvirus family were affected. The in vitro antiviral potencies of the 18 arabinosides correlated with their efficiencies as substrates of the VZV-encoded thymidine kinase in all but one case. The arabinosides of 6-methylaminopurine and 6-dimethylaminopurine were the most potent analogs, with 50% inhibitory concentrations against VZV of 3 and 1 ,uM, respectively. They were not cytotoxic to uninfected MRC-5 cells, human Detroit 98 cells, or mouse L cells (50% inhibitory concentration, >100 pM). Neither 6-methylaminopurine arabinoside nor 6-dimethylaminopurine arabinoside was detectably phosphorylated by either adenosine kinase or 2'-deoxycytidine kinase. These two alkylaminopurine arabinosides were also resistant to deamination catalyzed by adenosine deaminase. The VZV-dependent phosphorylation of these nucleosides offers the possibility of a potent and highly selective therapy for VZV infection.
Acyclovir [ACV; 9-(2-hydroxyethoxymethyl)guanine; Zovirax) is the drug of choice in the treatment of a variety of herpesvirus infections. This nucleoside analog inhibits varicella-zoster virus (VZV) at concentrations greater than those required for the treatment of herpes simplex virus (HSV) infections both in vitro (16) and in vivo (21) . In VZV-and HSV-infected cells, the initial activation step of ACV is conversion to the monophosphate by virally encoded thymidine kinases (6, 10) . However, the HSV thymidine kinase is more efficient than the VZV enzyme in phosphorylating ACV. This relative inefficiency of ACV phosphorylation by the VZV-encoded thymidine kinase correlates with its diminished potency.
Adenine arabinoside (ara-A) is efficacious in the treatment of human VZV infections (31) . However, the toxicity of this agent precludes its general use (12, 17, 24) . Previously, the in vitro therapeutic index of 6-methoxypurine arabinoside for VZV was reported to be superior to that of ara-A (1). This report describes a series of N-substituted derivatives of ara-A as anti-VZV agents.
MATERIALS AND METHODS
Biology. The inhibition of the replication of VZV and of other viruses; the kinetic constants for adenosine kinase, 2'-deoxycytidine kinase, and the various thymidine kinases; the growth inhibition of MRC-5 cells; and the immobilization of purine nucleoside phosphorylase and uridine phosphorylase were determined as described previously (1) . Growth inhibition of D-98 cells and mouse L cells was determined by the vital dye neutral red assay described previously (29) .
ADA assay. Calf intestinal adenosine deaminase (ADA; 200 U/mg) was purchased from Boehringer Mannheim (Indianapolis, Ind.) and dialyzed to remove the ammonium sulfate. Adenosine deamination was assayed spectrophotometrically at 270 nm (extinction change [As] = -5.85 mM-1 cm-1), 25°C, and pH 6.8 by progress curve analysis as described previously (28) . The conversion of 6-methylami-* Corresponding author. nopurine arabinoside to hypoxanthine arabinoside (ara H) was similarly assayed (Ar = -12 mM-1 cm-' at 270 nm).
Conversion of ara-A to ara-H was monitored at 265 nm (Ac = -8.2 mM-1 cm-'), and the kinetic constants were determined from initial velocity analysis. Inhibition assays were also analyzed by the progress curve method (28) .
Physical characterization of compounds. Elemental analyses of all the compounds listed in Table 1 Syntheses. 6-Chloropurine, 2,6-dichloropurine, 2-amino-6-chloropurine, and various substituted amines were from Aldrich Chemical Co. (Milwaukee, Wis.) and Sigma Chemical Co. (St. Louis, Mo.). 6-Methylamino-, 6-dimethylamino-, and 6-anilinopurine were from Sigma. 2-Fluoroadenine and 6-cyclohexylaminopurine were prepared by previously published procedures (9, 11) . Except for 6-cyclohexylaminopurine, the aglycones listed in Table 1 that were not commercially available (compounds ld, le, lf, lg, lh, 5, and 6) were prepared by displacement reactions involving 6-chloropurine or 2-amino-6-chloropurine and the appropri-ate amine. A typical amination procedure is described in detail below.
6-Propylaminopurine. 6-Chloropurine (3.85 g, 0.025 mol) and propylamine (2.3 g, 0.039 mol) were added to 25 ml of acetonitrile and heated at reflux for 18 h. The solvent was removed in vacuo, and the residue was purified by flash chromatography with CH3CN-H20 (95:5). Product-containing fractions were combined, and the solvent was removed to yield 2.66 g (60%) of propylaminopurine: melting point, 242 to 244°C; TLC silica gel Rf, 0.45 (CH3CN-H20 6-Methylamino-9-(j8-D-arabinofuranosyl)-9H-purine (compound la). 6-Methylaminopurine (6.7 mmol, 1 g) and uracil arabinoside (7.04 mmol, 1.79 g) were combined with 50 ml of 10 mM potassium phosphate (pH 7.4). Uridine phosphorylase (16,000 IU) and purine nucleoside phosphorylase (14,400 IU) were added, and the reaction was stirred at 35°C overnight. After the addition of CH30H (150 ml), the reaction was filtered, and the filtrate was chromatographed twice in CH3OH-H20 (9:1) on a column (2.5 by 9 cm) of Dowex-1-hydroxide (AG1-X2). Fractions containing product were combined, the solvent was removed, and the residue was dissolved in C2H5OH-H20 (1:1). 6-Dimethylamino-9-(j8-D-arabinofuranosyl)-9H-purine (compound lb). 6-Dimethylaminopurine (0.288 mol, 47 g) and uracil arabinoside (0.346 mol, 84.3 g) were suspended in 4 liters of 10 mM potassium phosphate (pH 7.4). Uridine phosphorylase (250,000 IU) and purine nucleoside phosphorylase (2,500,000 IU) adsorbed onto 1.2 liters of DEAE cellulose were added, and the suspension was stirred at 50°C. Five days later, the reaction mixture was filtered, and the filtrate was stored at 3°C overnight. The resulting precipitate was collected, washed with cold water, and dried under vacuum to yield 51. The recovered immobilized enzyme was washed with 1.2 liters of 10 mM potassium phosphate (pH 7), and the filtrate was combined with the filtrate described above. This solution was adjusted to pH 10.5 with ammonium hydroxide and then chromatographed on a column containing 1 liter of Dowex-1-formate (5 by 45 cm) resin. The column was eluted with CH30H. Fractions containing product were combined, and the solvent was removed. The residue was recrystallized from CH3OH-H20 (4:1) to give 19.1 g of compound lb: melting point, 199°C. This sample of compound lb had NMR and MS identical to those described above.
6-Dimethylamino-8-bromo-9-(q-D-arabinofuranosyl)-9H-purine (compound lc). Bromine (2.27 g, 0.78 ml) and sodium acetate (1 M, 16 ml) (pH 4) were combined and mixed for 2 min, after which compound lb (0.5 g, 1.7 mmol) was added.
After 15 6-Ethylamino-9-(,-D-arabinofuranosyl)-9H-purine(compound ld). 6-Ethylaminopurine (0.5 g, 3 mmol) and uracil arabinoside (1.49 g, 6 mmol) were combined in 25 ml of 10 mM potassium phosphate (pH 7.4). Uridine phosphorylase (28,500 IU) and purine nucleoside phosphorylase (228,000 IU) adsorbed onto DEAE cellulose were added, and the suspension was stirred at 60°C. Three days later, the reaction was filtered, the pH of the filtrate was adjusted to 10.6, and the filtrate was chromatographed on a column containing Dowex-1-formate resin (2.5 by 18 cm) in CH3OH-H20 (9:1). The solvent was removed, and the product was further purified by flash chromatography with CHCl3-CH30H (9:1) 6-N-Ethylmethylamino-9-( -D-arabinofuranosyl)-9H-purine (compound le). 6-N-Ethylmethylaminopurine was prepared by nucleophilic displacement of the chlorine group on 6-chloropurine by N-ethylmethylamine in CH3CN. 6-NEthylmethylaminopurine (0.5 g, 2.8 mmol) and uracil arabinoside (1.38 g, 5.6 mmol) were suspended in 575 ml of a solution of 10 mM potassium phosphate containing 0.04% potassium azide (pH 7.4) and 10% (vol/vol) n-propanol. Uridine phosphorylase (6, 000 IU) and purine nucleoside phosphorylase (8, 400 IU) were added, and the solution was stirred at 37°C. Nineteen days later the reaction was filtered; the filtrate was chromatographed on a column (2.5 by 13 cm) containing Dowex-1-hydroxide resin in CH3OH-H20 (9:1). Fractions containing product were combined, and the solvent was removed. The residue was dissolved in 30% n-propanol-water and purified by chromatography on BioRad P-2 resin 6-N,N-Diethylamino-9-("-D-arabinofuranosyl)-9H-purine (compound lf). 6-N,N-Diethylaminopurine (0.5 g, 2.6 mmol) and uracil arabinoside (1.27 g, 5.2 mmol) were combined in 25 ml of 10 mM potassium phosphate (pH 7.4). Reaction conditions and product isolation were identical to those described above for compound ld, except that the mobile phase for the flash chromatography was CHCl3-CH30H 6-n-Propylamino-9-(13-D-arabinofuranosyl)-9H-purine (compound lg). 6-n-Propylaminopurine (0.5 g, 2.8 mmol) and uracil arabinoside (1.37 g, 5.6 mmol) were combined in 25 ml of 10 mM potassium phosphate (pH 7.4). Reaction conditions and product isolation were identical to those described above for compound lf. This procedure resulted in 0.621 g of compound lg: TLC Rf, 0.56 (silica gel, CHCl3-CH30H 8:2); MS, ci (CH4) 310 (M + 1), 178 [(M + 1)-pentose].
6-Isopropylamino-9-(,B-D-arabinofuranosyl)-9H-purine (compound lh). 6-Isopropylaminopurine (0.5 g, 2.8 mmol) and uracil arabinoside (1.38 g, 5.6 mmol) were combined in 100 ml of 10 mM potassium phosphate (pH 7.4). Reaction conditions and product isolation were identical to those described above for compound ld. This procedure resulted in 0.622 g of compound lh: TLC Rf, 0.8 (cellulose, H20);
6-n-Hexylamino-9-(i-D-arabinofuranosyl)-9H-purine (compound li). 6-n-Hexylaminopurine (0.96 g, 4.4 mmol; Sigma) 1438 KOSZALKA ET AL.
SELECTIVE AGENTS AGAINST VARICELLA-ZOSTER VIRUS 1439 and uracil arabinoside (1.6 g, 6.6 mmol) were combined in 310 ml of 10 mM potassium phosphate (pH 7.4) containing 12% n-propanol. Reaction conditions were identical to those described above for compound ld. After 112 days, the reaction mixture was filtered and the precipitate that formed overnight at room temperature was discarded. 2-Chloro-6-methylamino-9-(P-D-arabinofuranosyl)-9H-pu-
in benzene was combined with 35 ml of benzene containing 2.1 g of methylamine at room temperature in a sealed bomb for 4 days. The bomb was cooled thoroughly in ice, and the contents were filtered to remove the methylamine hydrochloride. The solvent was removed to give an oil that was combined with an oil from a reaction of the same scale that was conducted at 125°C. The total weight was 11.4 g. TLC indicated that this material was a mixture of starting material and mono-and dimethylamino compounds. The oil was purified by flash chromatography with acetone-cyclohexane (3:7) as the eluant. The component running below the starting material (TLC, silica gel acetone-cyclohexane [3:7] ) was collected, and the solvent was removed to yield 4.8 g of 2-chloro-6-methylamino-2' ,3' ,5'-tri-O-benzyl-9-(,-D-arabinofuranosyl)purine as an oil. A 1.1-g portion of this product in 40 ml of 2-methoxyethanol was added to a pressure bottle containing palladium chloride (0.87 g) that was prereduced in a Parr apparatus. This was hydrogenated at 50 lb/in2 for 30 min, with the hydrogen atmosphere changed after 15 min. 2-Amino-6-methylamino-9-( -D-arabinofuranosyl)-9H-purine (compound 5). 2-Amino-6-methylaminopurine (0.5 g, 3 mmol) and uracil arabinoside (1.49 g, 6 mmol) were combined in 100 ml of 10 mM potassium phosphate (pH 7.4). Uridine phosphorylase (9,000 IU) and purine nucleoside phosphorylase (12,600 IU) were added, and the suspension was stirred at 35°C. Twenty-one days later, the reaction was filtered and the filtrate was pH adjusted to 10.5. The product was purified by chromatography on a column containing Dowex-1-formate resin (2.5 by 7 cm) in CH3OH-H20 (9:1). The residue was dissolved in n-propanol-water (3:7) and 2-Amino-6-dimethylamino-9-( 1-D-arabinofuranosyl)-9H-purine (compound 6). 2-Amino-6-dimethylaminopurine (0.5 g, 2.8 mmol), uracil arabinoside (1.37 g, 5.6 mmol), uridine phosphorylase (9,000 IU), and purine nucleoside phosphorylase (12,600 IU) were combined in 100 ml of 10 mM potassium phosphate (pH 7.4). Reaction conditions and product isolation were identical to those described above for compound ld, except that the reaction time was 15 days, the mobile phase for flash chromatography was CHC13-CH30H (8:2) , and the product was dissolved in n-propanol-water 
RESULTS AND DISCUSSION
Chemical methods for the synthesis of purine arabinosides involve multistep procedures (13, 14, 22, 26 ). An alternative procedure has been described that facilitates this synthesis by transferring the arabinosyl moiety from a pyrimidine arabinoside to the purine aglycone (15 enzyme is exemplified with the synthesis of 6-dimethylamiCytotoxicity. The results of the growth inhibition assay for nopurine arabinoside (see Materials and Methods). the 18 arabinosides in Table 3 show that only ara-A and Chemical formulas, melting points, and UV absorbance compound 4 are appreciably toxic to cultured human D-98 data for the purine arabinosides prepared for this study are and mouse L cells. The cellular toxicities of both of these given in Table 1 . Proton NMR data are given in Table 2. analogs are well-known (2, 7, 20) . b300-MHz spectrum.
C-, NMR sample size was 0.4 mg, and the hydroxyl groups were exchange broadened.
1440 KOSZALKA ET AL. The growth inhibition of uninfected MRC-5 cells by selected nucleosides is also given in Table 3 . The slight toxicities of compounds la and lb and the more significant toxicity of compound 2 was reversed upon the addition of the adenosine deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) (25) . As expected, the toxicity of ara-A was potentiated by blocking its deamination. Other than compound 4, none of the arabinosides tested were cytotoxic to uninfected MRC-5 cells.
There was no apparent correlation between the cytotoxicities of the 18 arabinosides tested and their antiviral effects. Antiviral activities and enzyme correlations. The anti-VZV assay assessed the ability of compounds to inhibit replication of the virus in MRC-5 cells (5, 29) . Ara-A was moderately inhibitory to the replicating virus (Table 3) . However, its potency was significantly increased in the presence of EHNA (Table 3) . Substitution of a methyl or a dimethyl group on the 6-amino group of ara-A (compounds la and lb, respectively) resulted in analogs that were more active than ara-A in the absence of EHNA and that were equally as active as ara-A in the presence of EHNA (Table 3 ). Both compounds la and lb were efficiently phosphorylated by the VZV-encoded thymidine kinase. These methyl substitutions also diminished the substrate efficiency of both analogs with ADA (Table 4) .
Further increases in the bulk and hydrophobicity of the alkylamino substituent in the purine 6 position proved to be detrimental both to the antiviral activity and to the rate of phosphorylation by VZV thymidine kinase. Substitution of ethyl for methyl, exemplified by compound le, increased the 50% inhibitory concentration (IC50) to 10 ,uM and decreased the substrate efficiency eightfold with VZV thymidine kinase. Further extension of the 6-substituent to diethylamino (compound lf) resulted in the loss of all antiviral activity.
VOL. 35, 1991 Extension of a mono-substitution at the 6-amino position from methyl (compound la) to ethyl (compound ld) caused a fivefold increase in the IC50 (Table 3 ). The higher IC50 with compound ld was also reflected in a sixfold decrease in substrate efficiency. Further extension to n-propyl (compound lg) eliminated any observed antiviral effect. However, compound lg was a substrate for VZV thymidine kinase. This exception to the correlation of antiviral activity to the phosphorylation efficiency of VZV thymidine kinase suggests that additional metabolic steps after phosphorylation may be required to inhibit VZV. The trend of increasing IC50s with increasing bulk was further exemplified by compound li. This analog was devoid of antiviral activity and was not detectably phosphorylated by the virally encoded thymidine kinase (Table 3) . Branching of the a carbon of the 6-N-substituent (compound lh) also decreased the antiviral activity compared with that of compound ld. Cyclization of the n-hexyl chain (compound lj) resulted in a compound devoid of antiviral activity. This lack of activity correlated with the absence of detectable phosphorylation by the VZVencoded thymidine kinase (Table 3) .
Compounds substituted at the purine 2 position were prepared in an attempt to limit catalysis by ADA and to enhance the antiviral activity. It is well documented that the rate of enzymatic deamination of adenosine and ara-A can be lowered by the substitution of a halogen in the purine 2 position (3, 4, 7, 19, 20) . Compound 4 was efficiently phosphorylated by the virally encoded thymidine kinase and exhibited anti-VZV potency greater than that of ara-A and equivalent to that of ara-A in the presence of EHNA (Table  3) . Although these properties are desirable for a potential anti-VZV candidate, clinical evaluation of compound 4 as an antileukemic agent has shown it to be more toxic than ara-A (8, 18) .
Substitution at the 2 position of ara-A with an amino group to give compound 2 had no effect on the anti-VZV activity compared with that of ara-A. However, contrary to the result observed with ara-A, compound 2 was devoid of anti-VZV activity when it was tested in the presence of EHNA (Table 3 ). These data suggest that the activity observed in the absence of EHNA is most likely due to the generation of guanine arabinoside. Guanine arabinoside has been shown to have anti-VZV activity equivalent to that observed with compound 2 in the absence of EHNA (1) .
The addition of an amino group to the 2 position of a purine arabinoside that is resistant to deamination by ADA and that is active against VZV proved to be detrimental. Compounds 5 and 6 had IC50s that were 17-and 39-fold higher, respectively, than those of the corresponding 2-unsubstituted compounds (Table 3) . Additionally, the VZV thymidine kinase substrate efficiencies of compounds 5 and 6 were significantly lower than those of the corresponding 2-unsubstituted analogs, compounds la and lb. Substitution of chlorine in the 2 position of compound la (compound 3) resulted in the loss of all anti-VZV activity. Substitution of a bromine at the 8 position of compound lb was unfavorable (compound lc). This result correlated with the inefficient phosphorylation observed for compound lc with VZV thymidine kinase (Table 3) .
Other viruses. The antiviral properties of the most potent anti-VZV analogs (compounds la, lb, and ld) against other viruses in the herpesvirus group were also examined. At concentrations below 100 ,uM, none inhibited the replication of herpes simplex virus type 1 or type 2, cytomegalovirus, or Epstein-Barr virus. Studies with other nucleoside kinases. The arabinosides of adenine, 6-methylaminopurine (compound la), and 6-dimethylaminopurine (compound lb) were also studied as substrates of thymidine kinases isolated from HSV type 1-infected cells and H9-uninfected cells (Table 5 ). The HSV type 1-encoded thymidine kinase catalyzed the slow phosphorylation of these arabinosides, while none of these compounds were phosphorylated with the thymidine kinase from uninfected H9 cells. In contrast, the VZV-encoded thymidine kinase readily catalyzed the phosphorylation of all three compounds (Table 5) .
A major difference between ara-A and compounds la and lb was that neither 2'-deoxycytidine kinase nor adenosine kinase catalyzed the phosphorylation of the latter two compounds (Table 5 ). Contrary to this observation, calf thymus 2'-deoxycytidine kinase catalyzed the rapid phosphorylation of ara-A. Substrate activity with adenosine kinase from rabbit muscle was also observed with ara-A but not with either compound la or lb (Table 5 ) (1). The lack of observed substrate activity with these constitutive enzymes suggests that compounds la and lb may be phosphorylated only in VZV-infected cells.
ACV is widely used for the treatment of HSV and VZV infections. In vitro, the IC50 for ACV inhibition of VZV replication is 15 ,uM (Table 3) . Compounds la and lb are clearly more potent than ACV and are worthy of further evaluation. 1442 KOSZALKA ET AL.
